PET/CT in preclinical drug or device development using clinical systems

1017 Learning Objectives 1. To introduce how pre-clinical PET/CT imaging can be performed as part of drug or device development using state of the art human sized systems. 2. To review the requirements and appropriate policies of managing animals including NHP9s in current clinical devices. 3. To present some case demonstrations of innovative applications. While the use of PET is already an important component of rodent or tissue imaging within pre-clinical development and trials, the use of human sized PET/CT with larger animals: canine, procine and non human primates (NHP) is still in its relative infancy. Using a state of the art PET/CT system Gemini 64 TOF (Philips, Cleveland) with full hot lab and injector capabilities installed on a 509 mobile coach, we performed a portfolio of sponsored PET/CT studies to assess either drug or device effectiveness. We present our operational approach and processes for species and goal adapted imaging. These imaging studies require a well established imaging and handling protocol and are a substantial team effort, however can be also performed highly efficiently with subject throughput of more than 10 per day. Our presentation will detail sample applications, performance characteristics as well as highlights of our operational procedures to increase awareness. The same approach can also be used for veterinary patients. Research Support Wright Center of Innovation in Biomedical Imaging and Battelle Health and Life Science